The Valve Wire

Executive Summary

Today's valve developments center on early data suggesting TAVR patients may benefit from tirzepatide therapy to reduce post-procedural valve dysfunction, FDA approval of a new TAVR system specifically for severe aortic regurgitation, and updated Medicare coverage guidance for TAVR procedures. Several landmark clinical trials continue to advance our understanding of transcatheter valve therapies, while industry stocks show mixed performance amid broader market uncertainty.

The structural heart field continues to grapple with expanding indications and emerging technologies, though clinicians should remain cautious about preliminary findings that lack long-term durability data. Today's developments highlight both the promise of adjunctive therapies like GLP-1 agonists in TAVR patients and the ongoing regulatory evolution supporting broader transcatheter access—though questions persist about optimal patient selection and long-term outcomes compared to surgical alternatives.

Aortic Valve (TAVR/TAVI)

[NOTABLE] Early findings from the TAVR-MET study suggest that tirzepatide, a GLP-1 receptor agonist, may reduce post-procedural valve dysfunction in TAVR patients. TCTMD reports these preliminary results warrant cautious optimism but require validation in larger, randomized trials. The mechanistic rationale for GLP-1 agonists in structural heart procedures remains unclear, and we should be skeptical of single-center or industry-sponsored early-phase data until peer-reviewed publication and longer follow-up become available.

The FDA has approved a new TAVR system specifically designed for severe aortic regurgitation—the Trilogy TAVR System. Medical Dialogues reports this approval addresses a challenging patient population where surgical options are often high-risk. However, severe aortic regurgitation represents a complex anatomical challenge for transcatheter therapy, with historical concerns about device migration and paravalvular leak. Long-term durability and comparative effectiveness data against surgical aortic valve replacement will be crucial.

Regulatory & Policy

CMS has issued updated National Coverage Analysis guidance for TAVR procedures, potentially affecting Medicare reimbursement and coverage criteria. The CMS update comes as TAVR continues expanding into lower-risk patient populations, though critics have raised concerns about whether transcatheter technologies are being adopted faster than the evidence base supports optimal patient selection.

Valve Industry Stocks

Edwards Lifesciences (EW)

Current Price: $82.76 (+$0.15, +0.19%)
6-Month Performance: +11.23%
Market Cap: $48.1B | P/E: 45.73 (trailing), 25.03 (forward) | Beta: 0.93
52-Week Range: $65.94 - $87.89
Analyst Target: $96.46 (range: $84.0 - $110.0, 28 analysts) - BUY
Next Earnings: April 22, 2026 (EPS est: $0.73, Rev est: $1.60B)

Edwards continues to show resilience with modest gains today and strong 6-month performance (+11.23%), though trading below recent highs. The company's TAVR and mitral franchises remain market leaders, but investors are watching competition intensify across all valve segments.

Medtronic (MDT)

Current Price: $86.74 (-$0.47, -0.54%)
6-Month Performance: -7.40%
Market Cap: $111.4B | P/E: 24.23 (trailing), 14.23 (forward) | Beta: 0.73
52-Week Range: $79.55 - $106.33
Analyst Target: $111.31 (range: $92.0 - $125.0, 26 analysts) - BUY
Next Earnings: May 20, 2026 (EPS est: $1.66, Rev est: $9.65B)

Medtronic faces pressure with 6-month declines (-7.40%) despite analyst optimism. The Evolut TAVR platform continues gaining share, but broader portfolio challenges and competitive dynamics in structural heart weigh on performance.

Abbott (ABT)

Current Price: $107.92 (-$0.57, -0.53%)
6-Month Performance: -19.91%
Market Cap: $187.5B | P/E: 29.01 (trailing), 17.29 (forward) | Beta: 0.74
52-Week Range: $105.27 - $139.06
Analyst Target: $132.64 (range: $113.0 - $158.0, 25 analysts) - BUY
Next Earnings: April 15, 2026 (EPS est: $1.15, Rev est: $10.99B)

Abbott shows the steepest 6-month decline (-19.91%) among major valve players, though MitraClip and structural heart revenues remain strong. Investors await clarity on growth trajectory and competitive positioning in expanding transcatheter markets.

Boston Scientific (BSX)

Current Price: $70.14 (-$1.14, -1.60%)
6-Month Performance: -28.30%
Market Cap: $104.1B | P/E: 36.15 (trailing), 17.92 (forward) | Beta: 0.7
52-Week Range: $67.56 - $109.5
Analyst Target: $103.27 (range: $83.0 - $124.0, 33 analysts) - STRONG BUY
Next Earnings: April 22, 2026 (EPS est: $0.79, Rev est: $5.19B)

Boston Scientific faces significant headwinds with the worst 6-month performance (-28.30%) despite strong analyst sentiment. While not primarily a valve company, its WATCHMAN and emerging structural heart portfolio contribute to overall cardiovascular growth expectations.

Anteris Technologies (AVR.AX)

Current Price: $8.21 (-$0.14, -1.68%)
6-Month Performance: +3.92%
Market Cap: $0.8B | Beta: 0.42
52-Week Range: $4.26 - $10.07
Analyst Target: $13.0 (1 analyst) - STRONG BUY

Anteris, focused on anti-calcification technology for bioprosthetic valves, shows modest 6-month gains (+3.92%) despite today's decline. As a smaller player, the company's DurAVR technology represents a potential differentiation strategy in competitive TAVR markets, though regulatory and commercialization risks remain elevated.

Market Outlook: Valve industry stocks continue facing mixed sentiment as transcatheter technologies mature and competition intensifies. While analysts remain generally bullish on long-term growth driven by aging demographics and expanding indications, near-term pressures from pricing competition, regulatory scrutiny, and questions about durability versus surgical alternatives are weighing on valuations. Edwards' resilience contrasts with broader sector weakness, suggesting investors are increasingly discriminating between market leaders and followers in this rapidly evolving space.

Clinical Trial Updates

Aortic

• NCT02701283: Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients - Status: ACTIVE_NOT_RECRUITING - Enrollment: 2223 - Sponsor: Medtronic Cardiovascular
• NCT07317804: Echo-Guided vs Fluoroscopy-Guided Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis（ECHO-TAVR） - Status: NOT_YET_RECRUITING - Phase: PHASE4 - Enrollment: 212 - Sponsor: China National Center for Cardiovascular Diseases
• NCT05149755: Evolut™ EXPAND TAVR II Pivotal Trial - Status: ACTIVE_NOT_RECRUITING - Enrollment: 650 - Sponsor: Medtronic Cardiovascular
• NCT04941248: Total-body 13N-NH3 PET/CT to Study the Blood Perfusion in Severe AS Patients Pre- and Post-TAVR in Whole Body - Status: COMPLETED - Enrollment: 34 - Sponsor: RenJi Hospital
• NCT07477002: Post-Dilatation Effect on TAVI Prostheses Expansion - Status: RECRUITING - Enrollment: 146 - Sponsor: Medical University of Vienna
• NCT06983938: This Study Will Evaluate the Safety and Potential Complications of Dual ProGlide vs Single ProGlide and Angioseal for Common Femoral Arteriotomy Closure Following Transcatheter Aortic Valve Replacement - Status: COMPLETED - Enrollment: 92 - Sponsor: Baylor Research Institute
• NCT07411768: Low-dose Colchicine for Thromboprophylaxis After Transcatheter Aortic Valve Replacement - Status: NOT_YET_RECRUITING - Enrollment: 116 - Sponsor: China National Center for Cardiovascular Diseases
• NCT04728698: [LANDMARK] PARTNER 3 Low Risk (5-year follow-up) - Status: WITHDRAWN - Phase: PHASE2 - Enrollment: 0 - Sponsor: Sorrento Therapeutics, Inc.

Mitral Repair

• NCT04198870: [LANDMARK] REPAIR-MR (MitraClip vs surgery for primary MR) - Status: ACTIVE_NOT_RECRUITING - Enrollment: 500 - Sponsor: Abbott Medical Devices - This pivotal trial comparing MitraClip to surgical repair in primary MR patients will provide crucial evidence on transcatheter versus surgical approaches in this lower-risk population.
• NCT05051033: [LANDMARK] PRIMATY (MitraClip vs medical therapy for secondary MR) - Status: RECRUITING - Enrollment: 450 - Sponsor: Annetine Gelijns - This trial addresses the controversial area of secondary MR following mixed results from COAPT and MITRA-FR studies.
• NCT03706833: [LANDMARK] COAPT (MitraClip for secondary MR - long-term follow-up) - Status: ACTIVE_NOT_RECRUITING - Enrollment: 1247 - Sponsor: Edwards Lifesciences - Long-term follow-up of this practice-changing trial continues to inform optimal patient selection for transcatheter mitral repair.

Mitral Replacement

• NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation - Status: ACTIVE_NOT_RECRUITING - Enrollment: 103 - Sponsor: Abbott Medical Devices
• NCT03339115: AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System - Status: ACTIVE_NOT_RECRUITING - Enrollment: 30 - Sponsor: Cardiovalve Ltd.
• NCT07470788: FIH ITA Study - Vesalius TMVr System for Symptomatic Degenerative Mitral Regurgitation - Status: NOT_YET_RECRUITING - Enrollment: 5 - Sponsor: Vesalius Cardiovascular Inc.
• NCT04101357: [LANDMARK] APOLLO (Tendyne TMVR) - Status: TERMINATED - Phase: PHASE1, PHASE2 - Enrollment: 54 - Sponsor: BioNTech SE - The termination of this trial highlights ongoing challenges in transcatheter mitral valve replacement technology.
• NCT03242642: [LANDMARK] Intrepid TMVR Pivotal - Status: RECRUITING - Enrollment: 1056 - Sponsor: Medtronic Cardiovascular - This large pivotal trial represents Medtronic's major push into transcatheter mitral replacement.
• NCT05490992: [LANDMARK] SAPIEN M3 TMVR Early Feasibility - Status: COMPLETED - Enrollment: 2448 - Sponsor: Pro Consumer Safety - Public Health Behavior Solutions

Tricuspid Repair

• NCT03904147: [LANDMARK] TRILUMINATE Pivotal (TriClip for TR) - Status: ACTIVE_NOT_RECRUITING - Enrollment: 572 - Sponsor: Abbott Medical Devices - This pivotal trial establishes TriClip as the first FDA-approved transcatheter tricuspid repair technology.
• NCT04097145: [LANDMARK] CLASP II TR (PASCAL for TR) - Status: RECRUITING - Enrollment: 870 - Sponsor: Edwards Lifesciences - Edwards' competing platform in the emerging tricuspid repair market.

Tricuspid Replacement

• NCT04482062: [LANDMARK] TRISCEND II (Evoque tricuspid replacement) - Status: ACTIVE_NOT_RECRUITING - Enrollment: 864 - Sponsor: Edwards Lifesciences - The largest tricuspid replacement trial to date, representing the next frontier in transcatheter valve therapy.
• NCT05071768: [LANDMARK] GATE Pivotal (NaviGate tricuspid replacement) - Status: COMPLETED - Enrollment: 31 - Sponsor: University of Manitoba

As transcatheter valve technologies continue expanding across all four cardiac valves, today's developments underscore both the promise and limitations of this rapidly evolving field. While early data on adjunctive therapies like tirzepatide offer intriguing possibilities, the structural heart community must remain grounded in rigorous evidence standards as we navigate an increasingly complex landscape of device options and patient selection criteria.